New way of screening potential treatments for TB

Scientists have developed a new way of screening potential treatments for Tuberculosis (TB) which may assist in the identification and prioritization of new therapies which could potentially reduce the duration of current TB treatment.
A major challenge to TB drug development is the lack of predictive preclinical tools. To address this deficiency, the team adopted a new high-content imaging-based approach capable of defining the killing kinetics of first line anti-TB drugs against intracellular Mycobacterium tuberculosis (Mtb) residing inside macrophages, or immune cells. Using a pharmacokinetic-pharmacodynamic (PK-PD) modelling approach the team demonstrates that the killing dynamics of the intracellular Mtb sub-population is critical to predicting clinical TB treatment duration. In addition, the model can be used to simulate new therapeutic regimens such as the use of higher doses of the antibiotic rifanpicin to predict the outcomes of clinical studies.
Source :      2017/4/26 08:15

خانه چاپ ارسال به دوستان نسخه متنی کوچک کردن متن بزرگ کردن متن دانلود خروجی پی دی اف خروجی میکروسافت ورد
0/10 (تعداد آرا 0 نفر )
Copyright © 2011 AASM. All Rights Reserved.